Ignite Creation Date:
2024-05-06 @ 2:39 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02098395
Status:
COMPLETED
Last Update Posted:
2017-02-09
First Post:
2014-03-25
Brief Title:
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
A 26-weeks Randomised Insulin Capped Placebo-controlled Double-blind Parallel Group Multinational Multi-centre Trial
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ADJUNCT TWO
Brief Summary:
This trial is conducted in Africa Europe and North America The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-005778-74 | EUDRACT_NUMBER | None | None |
| U1111-1138-0619 | OTHER | None | None |
| NL4770506014 | REGISTRY | None | None |
| REec-2014-0884 | REGISTRY | Spanish registry | None |